Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device sets $5000 a year cost challenge for RA anti-TNF drugs

This article was originally published in Scrip

Executive Summary

Rheumatoid arthritis patients who are not responding to conventional first-line drug treatment could, in three years, instead receive neuromodulation therapy from a device that is being developed by an emerging Californian medtech firm and that could cost around $5000 a year to provide. That represents a significant potential cost advantage and, therefore, market threat to anti-TNF drugs ad biologics that can cost $20,000-$30,000 a year or more.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC019417

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel